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Abstract
This review evaluates the health benefits of the functional food, conjugated linoleic acids (CLA) - a
heterogeneous group of positional and geometric isomers of linoleic acid predominantly found in
milk, milk products, meat and meat products of ruminants. During the past couple of decades,
hundreds of reports - principally based on in vitro, microbial, animal, and of late clinical trials on
humans - have been accumulating with varying biological activities of CLA isomers. These studies
highlight that CLA, apart form the classical nuclear transcription factors-mediated mechanism of
action, appear to exhibit a number of inter-dependent molecular signalling pathways accounting for
their reported health benefits. Such benefits relate to anti-obesitic, anti-carcinogenic, anti-
atherogenic, anti-diabetagenic, immunomodulatory, apoptotic and osteosynthetic effects. On the
other hand, negative effects of CLA have been reported such as fatty liver and spleen, induction of
colon carcinogenesis and hyperproinsulinaemia. As far as human consumption is concerned, a
definite conclusion for CLA safety has not been reached yet. Parameters such as administration of
the type of CLA isomer and/or their combination with other polyunsaturated fatty acids, mode of
administration (eg., as free fatty acid or its triglyceride form, liquid or solid), daily dose and duration
of consumption, gender, age, or ethnic and geographical backgrounds remain to be determined.
Yet, it appears from trials so far conducted that CLA are functional food having prevailing beneficial
health effects for humans.
Introduction
Conjugated linoleic acids (CLA) represent a heterogene-
ous group of positional and geometric isomers of linoleic
acid, which are predominantly found in milk, milk prod-
ucts, meat and meat products of ruminants [1,2]. Like
neutraceuticals, being minor lipids with supposed func-
tional food status, CLA are getting momentum in alleviat-
ing major killer diseases such as cancer, atherosclerosis,
and diabetes in humans [3-7]. Despite hundreds of
reports, it seems difficult to deduce a common mecha-
nism or molecular basis for the CLA action in in vivo con-
ditions, pertaining to reported health benefits [8].
Moreover, contrasting functionalities of CLA isomers
make this attempt more difficult [9,10]. Yet, the CLA
action at molecular level lies predominantly on the classi-
cal CLA-mediated activation of peroxisome proliferator-
activated receptors (PPARs) and subsequent "switching
on and/or off" of the target genes to elicit a host of bio-
chemical pathways [11]. As shown in Figure 1, during
gene regulation, the well characterised PPARs (α, β or γ
subtypes) bind to the peroxisome proliferator responsive
element (PPRE) on the nuclear DNA as heterodimers with
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one of the α, β or γ subtypes of the retinoic acid receptor
(RXR), which in turn, needs to be activated by cis-9-retin-
oic acid to effect target gene transcription [12,13]. Moder-
ate binding efficiencies of CLA isomers to PPAR subtypes
[2,14,15] and potentials for regulating the target genes as
shown by transactivation [2,16,17] and expression [18-
21] studies substantiate the above molecular mechanism
of action.
While PPARs are involved in the regulation of metabolic,
immune and inflammatory processes, only a very few
studies were conducted to integrate receptor-dependent
processes [22]. Due to the therapeutic significance of
selective agonists, the scientific understanding of PPARs
biology derives primarily from experiments that utilized
synthetic ligands to receptors [22]. In addition to the
PPAR-mediated actions, various inter-connected down-
stream molecular mechanisms exist in in vivo environ-
ment accounting for the reported biological functions of
CLA. Moreover, poly unsaturated fatty acids (PUFAs) like
CLA and their various metabolites can act at the level of
the nucleus, in conjunction with other nuclear receptors
and transcription factors, to affect the transcription of a
variety of genes. They include hepatocyte nuclear factor
(HNF)-4α, and liver × receptor, nuclear factor-κB (NFκB)
and the transcription factors sterol-regulatory element
binding protein (SREBP)[23]. Mitogen-activated protein
kinase/extracellular signal-related kinase (MEK/ERK) sig-
nalling through the autocrine/paracrine actions of inter-
leukins-6 and 8 opens up another important route for
adipocyte delipidation by CLA [24]. Modulatory effects of
CLAs [25] juxtaposed to PPAR-mediated gene expression
to effect novel molecular signalling pathways, which is
largely mediated though leptins [26,27], adiponectin
[28], eicosanoids [29], vitamins [30], immunoglobulins
[31,32], and thus altering membrane protein characteris-
tics [33] are also being elucidated. However, objective evi-
dences for these pathways are inconclusive, which
demand elaborate studies, especially the involvement of
hormones.
In this context, it is appropriate to have an overview into
the fundamental basis for major health benefits attributed
to CLA, viz., anti-obesitic, anti-carcinogenic, anti-athero-
genic, anti-diabetagenic, immunomodulatory, apoptotic
and osteosynthetic effects. Yet, they are coupled with neg-
ative effects like fatty liver and spleen, induction of colon
carcinogenesis and hyperproinsulinaemia [34-36].
CLA isomers
Positive health effects attributed to CLA are mainly based
on cell culture models and animal studies with compara-
tively less scientific evidences from direct studies on
humans [4]. Similarly, the molecular mechanism underly-
ing their effects in anti-obesity, anti-carcinogenic, anti-
diabetagenic, anti-artherogenic, immunomodulatory,
and even few negative effects are yet to be unveiled fully.
Natural products, specifically dairy fats, reportedly con-
tain over 25 CLA isomers and by chemical synthesis or
modification of the existing ones, novel isomers are being
added to this list [1,37]. Hence, the biological activities
attributed to CLAs have to be confirmed, if such attributes
are due to a single isomer or of the mixture. Being the pre-
dominant isomers, cis-9, trans-11-CLA (9-CLA, the
rumenic acid) and trans-10, cis-12-CLA (10-CLA) are the
primary focus of most of the studies evaluating the biolog-
ical activities of CLA [1,2], which are primarily derived
from linoleic acid, a typical n-6 fatty acid (Figure 2).
Hence, very often, all the CLA isomers are erroneously
termed as n-6 fatty acids, yet for instance, 9-CLA is an n-7
fatty acid. Interest in these isomers was stimulated by
results obtained in studies using commercially available
CLA, which is a mixture of approaximately equal amount
(~40% each) of these two isomers [38]. Currently, the
trend is in using a single isomer (mostly 9- or 10-CLA)
with purity above 90% [2,39]. Apart form the specific
anti-obesitic and hypocholesterolaemic effects of 10-CLA
[40], most of the rodent (rat and mice) studies suggest
that a CLA mixture (9- and 10-CLAs) could be more ben-
eficial for the management of insulin resistance [38]. Such
studies in obese humans, however, show that CLA do not
Proposed CLA-mediated signal transduction Figure 1
Proposed CLA-mediated signal transduction. The die-
tary lipid nutrient L (L = here CLA) crossing the cell mem-
brane with the help of specific membrane-bound fatty acid 
transporters and binds to tissue-specific fatty acid binding 
protein (FABP) in the cytosol; 2. The L/FABP complex enters 
in to the nucleoplasm, where L is transferred to the specific 
peroxisome proliferators activated receptor (PPAR) subtype; 
3. The L/PPAR complex heterodimerises with retinoic acid 
(RA)/retinoic acid receptor (RXR) subtype; 4. This het-
erodimer binds to the peroxisome proliferator responsive 
element (PPRE) on the target gene; and 5. Specific gene 
expression occurs, whose products act intra- or extracellu-
larly to elicit a host of various biological functionsNutrition & Metabolism 2009, 6:36 http://www.nutritionandmetabolism.com/content/6/1/36
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affect glucose metabolism or insulin sensitivity [41]. Thus,
the biological functions reported for CLA cannot be
explained by a single biochemical mechanism or of the
activity of a single isomer. It appears that 9-CLA elicit
more general biological events than 10-CLA
[9,19,21,33,42,43]. Dietary supplements of CLA as free
fatty acids [44] or its triglyceride form [45] is also a matter
of debate, which demands more evidences.
Among the naturally occurring CLAs, predominantly the
9-CLA but in small amounts also 10-CLA are synthesised
in the rumen of cattle, deer, sheep and goat by biotrans-
formation of forage-derived unsaturated fatty acids such
as oleic acid and linoleic acid [2]. The trans-Δ11-vaccenic
acid (t-VA), produced as a rumen biohydrogenation inter-
mediate from both linoleic acid and α-linolenic acid pro-
vides amajor alternate route for 9-CLA biosynthesis in
mammalian cells, including humans, via Δ9desaturation
by stearoyl-CoA desaturase (SCD) [2]. Strategies to
enhance milk fat CLA involve increasing rumen outflow
of t-VA and increasing SCD activity, and through these,
several-fold increases in the content of CLA in milk fat can
be routinely achieved through the use of diet formulation
and nutritional management of dairy cows [46]. CLA rep-
resent minor lipid nutrients in feed and food, in particular
in dairy beef products. Milk contains over 20 isomers of
CLA but the predominant one is 9-CLA (75-90% of total
CLA) [46]. Schmid et al. reviewed the intramuscular CLA
concentrations in meat and meat products originating
from different animal species, factors influencing these
concentrations, the estimated human daily intakes and
the percentage of CLA provided by meat and meat prod-
ucts [47]. Our group also demonstrated the endogenous
synthesis of 9-CLA from precursor t-VA in humans [48].
Anti-obesity
Considering anti-obesitic and hypolipidemic effects, it is
possible to modify body composition by supplementing
CLA to the diet. Major biochemical actions of CLA associ-
ated with anti-obesity are summarised in Table 1[49-54].
Dietary supplementation of CLA has been effective in
reducing the percentage of body fat and increasing the
percentage of body protein [41,55]. Studies with rodents,
pigs and cattle show that effects of CLA on body composi-
tion appear to be due in part to reduced fat deposition and
increased lipolysis in adipocytes [56], possibly coupled
with enhanced fatty acid oxidation in both muscle cells
and adipocytes as in rat [26]. Jiang et al. [8], in their cross-
species (cattle breeds: Wagyu × Limousin) study, found
SCD-1 gene to be a critical player in skeletal muscle fat
metabolism resulted in high amount of monounsaturated
fatty acids (MUFA) and CLA content, but with low
amount of saturated fatty acids. CLA mixture (9- and 10-
CLA) showed to suppress the SCD activity in porcine sub-
cutaneous adipose tissue [57].
Our group already demonstrated that dietary supplemen-
tation with trans-11- and trans-12-18: 1 MUFA increases 9-
CLA in human peripheral blood mononuclear cells lipids
(from 0.07 to 0.16%) without effects on biomarkers of
immune function and inflammation [48]. In the same
intervention study we found that higher body fat accumu-
lation was significantly associated with higher SCD-1 iso-
Structure of linoleic acid and its major CLA derivatives Figure 2
Structure of linoleic acid and its major CLA deriva-
tives. 1. Linoleic acid (typical n-6 PUFA); 2. cis-9, trans-11-
octadecadienoic acid (9-CLA, in fact an n-7 fatty acid); 3. 
trans-10, cis-12-octadecadienoic acid (10-CLA).
Table 1: Major biochemical actions of CLA on lipid metabolism.
Biochemical action Experimental evidence Ref
Preadipocyte proliferation Inhibited proliferation [49]
Preadipocyte differentiation Human preadipocytes do not differentiate in the absence of a PPARγ ligand like CLA [25]
Fatty acid oxidation Carnitine palmitoyltransferase activity increased by dietary CLA [28,50]
Adipose tissue lipid synthesis Inhibition of de novo lipogenesis through down regulation of acetyl-CoA carboxylase and fatty acid 
synthase
[51]
Lipolysis Increased lipolysis and decreased fat [52]
Energy expenditure Increased oxygen consumption and energy expenditure by 10-CLA [44]
Stearoyl-CoA desaturase Inhibition at protein or activity level, by post-translational modification [15]
Plasma leptin Decrease in serum leptin, a hormone regulating fat level [26,53]
Apotopsis Induce apoptosis in adipocytes [49]
Tumor necrosis factor-α Increased expression of TNFα and low fat [54]Nutrition & Metabolism 2009, 6:36 http://www.nutritionandmetabolism.com/content/6/1/36
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form expression in control women, who had 25% more
body fat mass than men [58]. Interestingly, after 42 days
of intervention, SCD-1 and glucose transporter genes
(GLUT 1 and 4) were 10 fold down-regulated in women,
but no significant change in men; this effect can be attrib-
uted to the endogenously synthesised 9-CLA [48,58,59].
In addition, we also found that stored fats had a strong
association with gender-based higher synthesis of hor-
mones such as leptin. Female subjects possessed signifi-
cantly higher plasma leptin and lower adiponectin
concentrations than their male counterparts [59]. This
clearly indicates hormonal-related gene regulation [60].
As SCD-1 is the rate-limiting enzyme in the synthesis of
MUFA, it becomes the critical control point regulating
hepatic lipogenesis and lipid oxidation [61]. The inhibi-
tory effects of 10-CLA on SCD-1 have been consistent,
regardless of the model or species [62]. Treatment with
mixed isomers, or more specifically 10-CLA, decreases
either the activity or abundance of SCD-1 in a human
breast cancer cells, human hepatocytes and murine adi-
pocytes [62].
Paton and Ntambi demonstrated SCD-l to be a key
enzyme in regulating hepatic lipogenesis and lipid oxida-
tion; therapeutic manipulation of SCD-1 can be of benefit
in treatment of obesity and metabolic syndrome [63]. As
several manifestations of the metabolic syndrome and
type 2 diabetes mellitus are associated with alterations in
intracellular lipid partitioning, SCD1 has emerged as a
therapeutic target in the treatment of obesity and the met-
abolic syndrome, according to Dobrzyn and Ntambi [61].
Decreased adipocyte lipid synthesis is observed in a
number of studies. In vivo and in vitro evidences to date
suggest that there exist a multiple mechanism for the CLA-
mediated fat reduction, in addition to the PPAR-mediated
primary mechanism for CLA uptake. It seems that CLA
might act as an agonistic or antagonistic ligand for PPARγ
to control preadipocites [64]. Interestingly, 9- and 10-CLA
isomers equally reduced lipid deposition in porcine
preadipocytes with a preferential effect of 10-CLA and no
isomer distinction in human preadipocytes [64]. Moreo-
ver, CLA might facilitate decreased energy or food intake
and increased energy expenditure, decreased preadipocyte
differentiation and proliferation, decreased lipogenesis,
and increased lipolysis and fat oxidation [5]. Decreased
plasma leptin, increased adipocyte apoptosis and
increased plasma tumour necrosis factor-α (TNFα) are
other possible routes [64]. The fundamental basis for the
generalised mechanism lies in the modulation of the tran-
scription factor PPARγ or adipocyte determination and
differentiation-dependent factor 1, which would elicit a
cascade of multiple metabolic pathways including inhibi-
tion of SCD-1 [64,65]. Delipidation by mitogen-activated
protein kinase or extracellular signal-related kinase signal-
ling is evidenced by the anti-proliferative activity of CLA
in MCF-7 cells [66]. Additional to major mediator effect of
TNFα in inflammatory responses, the correlation between
its increased expression and decrease in fat deposition
[48,67] may be due to increased lipolysis [26] and
decreased lipoprotein lipase activities [68].
Studies made on animals and humans show that the con-
sumption of CLA leads to loss of fat and total body
weight, reduces the plasma concentrations of total and
low density lipoprotein (LDL)-cholesterol, and has an
anti-inflammatory effect (Table 1). Gene-by-diet interac-
tions play an important role in the prevention of several
diseases. To elaborate this concept, we investigated the
changes in gene expression in monocytes upon interven-
tion with two trans fatty acids (trans-11 18:1 and trans-12
18:1) and endogenous synthesis of CLA from t-11 18:1 (t-
VA) as precursor in humans [59]. Expression patterns of
20 candidate genes involved in glucose and lipid metabo-
lism have been assessed, which were chosen on the basis
of the interaction of their proteins in fatty acid signalling
and are partly regulated by PPAR and have a PPRE in their
promoter. Interestingly, the expression patterns revealed
prominent gender-based differences in gene expression
[59].
Ntambi's group demonstrated that loss of SCD-1 function
protects mice from developing obesity [63]. This is likely
due to decreased synthesis of long-chain MUFAs such as
oleate, a preferred substrate for triglyceride synthesis. The
inhibitory effects of 10-CLA on SCD-1 have been consist-
ent, regardless of the model or species. Treatment with
mixed isomers, or more specifically 10-CLA, decreases
either the activity or abundance of SCD-1 in a human
breast cancer cells, human hepatocytes and murine adi-
pocytes [63]. In humans, although it is indicated that 10-
CLA is the antiadipogenic isomer, the effects of CLA on fat
deposition are less significant and more equivocal as com-
pared to results observed in animals [69]. A need exists to
establish whether interactions exist between dietary CLA
supplementation and factors such as energy intake, die-
tary fatty acid composition, especially PUFA in humans.
Proposed antiobesity mechanisms of CLA include
decreased energy/food intake and increased energy
expenditure, decreased preadipocyte differentiation and
proliferation, decreased lipogenesis, and increased lipoly-
sis and fat oxidation [69]. Brown and McIntosh [62] pro-
posed that 10-CLA exerts its partial inhibition of
adipocyte differentiation by reducing the expression of
PPAR γ and its downstream targets that are critical for fatty
acid (i.e., ACBP, A-FABP, LPL, perilipin) and glucose
metabolism (i.e., GLUT4, ACC, SCD-1). 10-CLA
decreased the triglyceride content of newly differentiated
human adipocytes from stromal vascular cells by inducing
MEK/ERK signaling through the autocrine/paracrineNutrition & Metabolism 2009, 6:36 http://www.nutritionandmetabolism.com/content/6/1/36
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actions of interleukins-6 and 8 [24]. The 10-CLA may acti-
vate IL-6 and IL-8 gene expression and secretion, which is
dependent on an autocrine activation of MEK/ERK signal-
ling in nonadipocyte stromal vascular cells, which in turn,
through paracrine actions impacts MEK/ERK signalling in
newly differentiated adipocytes, leading to insulin resist-
ance and delipidation [24].
Van Erk et al. [70] observed in humans that upon con-
sumption of a specially designed spread with higher levels
of medium-chain triglycerides and PUFA (18:2 and 18:3),
CLA favoured higher expression of genes related to lipid
metabolism and lower activity of inflammatory genes. A
short-term diet change elicited the activity of genes that
play a role in inflammatory processes in fat tissue of peo-
ple who are overweight [70]. This technique is an example
of nutrigenomics research, and it allows to investigate the
effect of complex mixtures of functional food ingredients
on fat tissues. Such findings show that genes in fat tissue
are sensitive to diet changes. The result also strengthens
the hypothesis that fat tissue is actively involved in the
development of obesity-related disease. Nutrigenomics
defines how food and ingested nutrients influence the
genome (personalised nutrition) [70]. Though the above
studies throw some light into the potential benefits of
CLA in humans, additional studies are required to clearly
define optimal level of CLA intake, short and long term
effects and side effects (if any) of each individual CLA iso-
mer in order to determine its safety and efficacy [71].
Therefore, long-term randomized clinical trials, control-
led with placebo, need to be made in large samples of
patients to evaluate the efficacy and safety of CLA isomers
before its indiscriminate use in human beings can be rec-
ommended [5]. Moreover, such trials have to be repli-
cated in other labs too, preferably in different continents
and races with varying food styles.
Anti-carcinogenesis
CLA inhibits cancer by blocking the growth and metastatic
spread of tumours. CLA is fast acting, and begins to
inhibit both malignant and benign tumours almost
immediately [15]. 10-CLA seems to work preferentially
through modulation of apoptosis and cell cycle control,
while 9-CLA isomer affects arachidonic acid metabolism
[42]. Kritchevsky [72] reviewed the inhibitory effects of
CLA on chemically-induced skin, stomach, mammary or
colon tumours in mice and rats. In vitro studies in murine
myeloid leukaemia (WEHI-3B JCS) [73] and human
colorectal (HT-29, MIP-101) and prostate (PC-3) colorec-
tal [74] cells, as well as in vivo human studies on breast
[75,76] and prostate [42] cancers showed CLA's best anti-
proliferative effects. Cellular mechanisms of modulation
of carcinogenesis by CLA are numerous and complex. It
may be via reduction in cell proliferation [77,78], lipid
oxidation [5], vitamin A [79] and prostaglandin (PG)
[80,81] metabolisms. It is also possible that CLA may
interfere with cell transformation through signal trans-
duction [82]. Furthermore, the anticarcinogenic proper-
ties of CLA are, at least partially, attributed to thier ability
to interrupt the n-6 PUFA metabolic pathway for the bio-
synthesis of eicosanoids, including PGs [80,81]. Altered
phospholipid-associated fatty acid metabolism and
eicosanoid (20-carbon derivatives viz, PGs, thrombox-
anes, leukotrienes, hydroxyeicosatetraenoic acids) forma-
tion are yet other thrust areas of active research.
Eicosanoids modulate cell proliferation, inflammation,
local and systemic immunity, platelet aggression and tis-
sue diffrentiation. Free CLAs could compete with other
fatty acids to be incorporated in the phospholipids and
modifies subsequent eicosanoid production. Dietary CLA
reduce PG-E2 [83] and others (PGF2α, leukotriene-B4, leu-
kotriene-C4) derived from arachidonic acid metabolism
[29,84,85]. Other possible route for the CLA mediated
reduction of arachidonate-derived eicosanoids is through
inhibition of cyclooxygenase (COX) 1 and 2. This include
pathways for arachidonic acid metabolism [42], apoptosis
(bcl-2) and cell cycle control (p21(WAF/Cip1)) [42,43].
Cell cycle and apoptosis
CLAs could alter growth of neoplastic cells by influencing
cell replication, interfering with components of cell cycle,
or increasing cell death by promoting necrosis or/and
apoptosis. Necrosis generally result from insult or toxicity
reaction and triggers inflammation, whereas apoptosis is
a distinct energy requiring process of programmed cell
death, characterised by DNA fragmentation, chromosome
condensation, nuclear fragmentation, formation of apop-
totic bodies, and inversion of phosphatidylserine in the
plasma membrane [86]. It is expected that CLA could
reduce cell proliferation by blocking DNA synthesis [87]
and cell cycle proteins [42,88] that regulate this process,
and that CLA may support elevated apoptosis primarily by
suppressing the expression of antiapoptotic bcl-2 gene
[29]. With different cell lines, CLA was able to increase the
IL-2 and IFN-γ via modulation of protein kinase activity
and production of oxidant species, which significantly
inhibited proliferation [89], and it appears to be the func-
tion of relative content of specific isomers and their ability
to elicit a p53 response that leads to cell growth arrest by
inhibiting the expression of factors required for G1 to S-
phase transition including cyclins D1 and E [90], or by the
inhibition of the insulin-like growth factor-I receptor sig-
nalling pathway [87].
Anti-atherosclerosis 
Atherosclerosis is a progressive disease of medium and
large arteries by the accumulation of lipids in the inflam-
matory cells (foam-cell formation), cellular proliferation,
platelet adherence and aggression, and calcium deposi-
tion [91,92]. CLA are a potent anti-atherogenic dietaryNutrition & Metabolism 2009, 6:36 http://www.nutritionandmetabolism.com/content/6/1/36
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fatty acid in animal models of atherosclerosis by activat-
ing PPARs [93,94]. One would expect (a) decrease in
atherogenic lipoprotein plasma levels such as very low,
LDL-cholesterols and increase in anti-atherogenic high
density lipoprotein cholesterol (HDL) through increases
in apo A-I and apo A-II synthesis; (b) overexpression in
HDL receptors capable of increasing cellular cholesterol
efflux; and (c) decrease in vascular inflammation by
repressing nuclear NFkB and apo A-I transcriptional activ-
ity and they would reduce thrombosis risk by inhibiting
tissue factor and fibrinogen synthesis [59,95]. Despite a
few studies [5,40,43,96], no conclusive evidences involv-
ing CLA isomers are available to substantiate the above
signalling pathways proposed for drugs. Interestingly,
ratios of the LDL cholesterol to HDL cholesterol and total
cholesterol to HDL cholesterol were significantly reduced
in CLA-fed rabbits with less atherosclerosis [36,62].
Anti-diabetes
Diabetes can be caused by too little insulin (type I), resist-
ance to insulin (type II), or by both. Supplementing the
diet with CLA may lead to better disease management in
diabetics, especially type II. Many studies strongly suggest
that the 10-CLA isomer may be the bioactive isomer of
CLA to influence the body weight changes observed in
subjects with type II diabetes, reviewed by Belury et al.
[97]. Brown et al. observed that during delipidation proc-
ess, 10-CLA exerts a cascade of molecular actions by down
regulating the expression of PPAR γ and its downstream
targets that are critical for fatty acid and glucose metabo-
lism, which eventually inhibits glucose and fatty acid
uptake and metabolism. [24].
Studies investigating the mechanisms by which CLA oper-
ates at the cellular level show that the primary targets for
CLA are members of the nuclear receptor family, particu-
larly the lipostat transcription factors; viz PPARα, PPARγ,
SREBP1c, and LXRα [38,41]. Consequently, the effects of
CLA on glucose metabolism are likely secondary effects
mediated through factors such as PPARγ coactivator 1[98]
that are controlled by these nuclear receptors. Or it could
be due to complex mechanisms by the regulation of the
expression of genes (like uncoupling proteins) important
in the regulation of adipogenesis, glucose and lipid
metabolism, and, perhaps, whole-body thermogenesis
[99]. Another possible action of CLA in alleviating hyper-
insulinemia (in Zucker diabetic fatty rats) is via the sensi-
tisation of the adiponectin, a recently discovered
hormone secreted by adipocytes that has been reported to
enhance insulin sensitivity [100]. Furthermore, determin-
ing the ability of CLA isomers to influence glucose and
lipid metabolism as well as markers of insulin sensitivity
is imperative to understanding the role of CLA, and thus
to aid in the management of type II diabetes and other
related conditions of insulin resistance [101,102].
Immunomodulation
In vitro studies of the use of immune cells and in vivo ani-
mal models demonstrate that CLA modulate immune
function. However, in contrast to the reports with animal
models, CLA feeding to young healthy women did not
alter any of the indices of immune status tested, and it sug-
gests that short-term CLA supplementation in healthy vol-
unteers is safe, but it does not have any added benefit to
their immune status [103]. Ringseis et al. found that CLA
inhibit TNFα-induced eicosanoid release from human
vascular smooth muscle cells with the interaction of
PPARγ [104]. Reports demonstrate that both the active
CLA isomers (9- and 10-CLAs) can elicit both the innate
and adaptive immune responses [105-107]. These effects
lie in the ability of CLAs to modify soluble factors or
mediators of immunity such as eicosanoids [108],
cytokines [109] and immunoglobulin production
[104,110]. Albers et al. [105] investigated the effects of
two different mixtures of 9- and 10-CLA glycerides [in the
ratio 50:50 (1.7 g) or 80:20 (1.6 g) per day, repectively
administered for 12 weeks] on human immune function.
They found that 50:50 ratio beneficially enhanced the
protective antibody levels to hepatitis B. CLA may alter
eicosanoid signalling via TNF-α, and thus affecting a range
of biological functions including antigen presentation
[19]. This would cause changes in the membrane charac-
teristics and changes in the activity of membrane proteins
that serve as ion channels, transporters, receptors, signal
transducers or enzymes [86]. The alternative hypothesis is
rooted in the fundamental PPAR-mediated signalling, via
expression of target genes involved in immune function
[19]. CLA can also protect against tissue breakdown due to
immune stimulation during periods of severe illness
[111,112]. This effect may be due to the modulation of
NFkB for negatively regulating the lipopolysaccharide-
induced inflammatory responses [108], or against the
catabolism and inflammatory effects induced by
cytokines, especially TNFα [19]. The immunomodulatory
effects of CLA may have application in livestock produc-
tion as an alternative to the use of feed antibiotics (func-
tional food), or as a means of improving the response to
vaccination and conferring disease resistance.
Song et al. investigated the effect of dietary CLA supple-
mentation (3 g/day; 50:50 mix of 9- and 10-CLA major
isomers) on the immune system and plasma lipids and
glucose of healthy human (male and female) volunteers
[113]. Interestingly, levels of plasma IgA and IgM were
increased with decreased plasma IgE levels. CLA supple-
mentation also decreased the levels of the proinflamma-
tory cytokines, TNF-α and IL-1β, but increased the levels
of the anti-inflammatory cytokine, IL-10. In addition to
these effects, delayed type of hypersensitivity response
was decreased during and after CLA supplementation,
coupled with no significant changes for plasma glucose,Nutrition & Metabolism 2009, 6:36 http://www.nutritionandmetabolism.com/content/6/1/36
Page 7 of 13
(page number not for citation purposes)
lipids, lymphocyte morphology. Very recently, Kwak et al.
observed in obese pre-menopausal Korean females that
CLA (9- and 10-CLA mixture) supplementation modu-
lated to the increased release of markers (C-reactive pro-
tein, IL10, IgM) related with inflammation and immune
function, and this effect was much more subtle than those
found in animals and few other clinical studies [114].
Bone formation
Mixed CLA isomers have been shown to have variable
effects on bone formation (ostheosynthesis) and resorp-
tion in animals. The variable effects of CLA on bone phys-
iology may be due to the different isomers present in
common commercial preparations of CLA, and the effects
of the predominant individual isomers (9- and 10-CLAs)
are not clear. Dietary CLA inhibits eddosteal bone resorp-
tion, increases endocortical bone formation, and modu-
lates the action and expression of COX enzymes, thereby
decreasing prostaglandin-dependent bone resorption
[115,116]. CLA also enhances calcium absorption from
diet, improve bone formation and reduce the rate of bone
resorption in adult OVX rats [117]. Since CLA can affect
inflammatory cytokines, it is hypothesized that CLA may
be a good tool for prevention or reduction of rheumatoid
arthritis symptoms in humans [109]. However, under the
conditions tested in this double-blind, placebo-controlled
trial in adult men, a CLA supplement of mixed isomers
did not affect markers of calcium or bone metabolism
[109]. Doyle et al. [118] found that supplementation with
CLA or placebo for 8 weeks had no significant effects on
markers of bone formation (serum osteocalcin and bone-
specific alkaline phosphatase) or bone resorption (serum
C-telopeptide-related fraction of type 1 collagen degrada-
tion products, urinary N-telopeptide-related fraction of
type 1 collagen degradation products, urinary pyridino-
line and deoxypyridinoline), or on serum or urinary cal-
cium levels in healthy adult men. Baseline levels of these
biochemical parameters were similar in both groups of
subjects. While the placebo had no effect, CLA supple-
mentation resulted in a three-fold increase in 9-CLA iso-
mer in total plasma lipids [118]. Platt et al. have found
that alkaline phosphatase activity in cell lysates as a
marker of early osteoblast differentiation in human oste-
oblast-like cells [119]. The 9-CLA increased the number
and size of mineralized bone nodules from 25 to 100 μM,
but the 10-CLA did not show such effect [119]. The
increase in mineralized bone nodule formation by 9-CLA
was accompanied by a variable increase in alkaline phos-
phatase activity. These results show that the 9-CLA
increases the formation of mineralized bone nodules
using bone cells of human origin, and provide evidence
for isomer-specific effects of CLA on bone health [119].
Safety concerns and human scenario
Though only positive health benefits of CLA have been
addressed here, some negative impacts of CLA could not
be ruled out [120]. Some human CLA supplementation
studies have often shown conflicting and less convincing
health benefits. The marked variations between studies
may reflect the isomer-specific effects of individual CLA
isomers, which can often have opposing effects [36]. Main
findings from the mice models are increased liver and
spleen weight [16,26] and insulin resistance [41,98]. CLA-
induced fatty liver hemorrhagic syndrome in birds [121]
is yet another facet. A major problem arising from human
studies related mainly to the gastrointestinal tract; data
indicate that 10-CLA can act as a cancer promoter in colon
carcinogenesis, possibly through pathways affecting NFkB
and cyclin D1 [122]. Though 10-CLA profoundly
decreased body fat in mice possibly through increased
energy expenditure, dietary CLA greatly increased the
activity and mRNA levels of various lipogenic enzymes
like hepatic Δ5- and Δ6- desaturases and SREBP-1 in the
liver [123]. A large increase in lipogenesis and accumula-
tion of triacylglycerol in the liver after CLA treatment may
represent the physiological response of the animal to
metabolize excess glucose to fatty acid for storage as tria-
cylglycerols in liver rather than in adipose tissue [123].
Therefore, there is a possibility that the counteraction of
CLA-mediated induction of hepatic lipogenesis aggravates
glucose intolerance and hyperinsulinemia, despite being
potentially effective in preventing fatty liver [123].
In obese men, 10-CLA induces hyperproinsulinemia that
is related to impaired insulin sensitivity (hyperinsulinae-
mic-euglycaemic clamp), independently of changes in
insulin concentrations [124]. As hyperproinsulinemia
predicts diabetes and cardiovascular diseases, the use of
weight-loss supplements containing 10-CLA cautions its
indiscriminate consumption. There may be divergent
effects of CLA isomers in obese or diabetic subjects com-
pared to the normal-weight or healthy subjects as well as
differences determined by gender and/or genetics, i.e., sin-
gle nucleotide polymorphisms in related genes [125].
Moreover, such studies need to be duplicated in other labs
giving emphasis to men and women, age groups, ethnic
background, or food style. The possible beneficial effects
of 10-CLA supplementation in decreasing body fat mass
have received a great deal of attention, but potential
adverse effects of CLA on the insulin balance have been
largely ignored [69]. This is paradoxical, because CLA-
mediated hyperinsulinemia has been observed in several
studies in mice. CLA-induced insulin resistance may be
related to the alterations of plasma leptin levels. Studies
have shown that CLA supplementation induced reduc-
tions of plasma leptin levels in various animal models
[69]. The inconclusive results in human supplementation
trials are due to the use of mixed isomers, which may
negate one another, resulting in no net change in adipos-
ity; moreover, doses used in human trials were much
lower than those used in animal studies [62]. 10-CLA
decreases the expression of PPAR γ in adipocytes, whichNutrition & Metabolism 2009, 6:36 http://www.nutritionandmetabolism.com/content/6/1/36
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could promote insulin resistance. These paradoxical find-
ings may arise from the use of mixed isomers of CLA or
the difference in experimental models used. In any event,
isomer-specific dose-titrated clinical studies combined
with mechanistic studies in cultures of primary cells
should provide the much needed insight on potential
human applications for CLA. Within various rodent spe-
cies and strains, dietary CLA exerts varying potencies;
therefore, the differences in species' sensitivities are of
great importance when trying to extrapolate rodent data
to the human situation [2,15].
Of late, over a hundred clinical studies regarding the effi-
cacy of CLA as functional food are available in literature.
A brief survey on the outcome of such studies shows that
the overwhelming beneficial effects of CLA impart posi-
tive outlook. Table 2[113,125-135] gives some of the
notable effects of CLA in humans, as evidenced by clinical
studies. It seems that 9- and 10-CLA are having contrast-
ing biological functions, but 10-CLA with more detrimen-
tal effects. However a 50:50 ratio of these isomers may
give better effect, as effected in immune function [105].
Normal CLA concentration in human body is 0.1% of the
total fatty acid composition [136]. Studies reveal that an
intake of about 2-3 g per day for 6 to 12 months by an
adult would impart optimum biological effects, which
would be long lasting too [137]. According to Fernie et al.
[138] CLA as triacylglycerol is the most suitable form for
consumption and that the 9- and 10-CLA isomers are
absorbed similarly into chylomicrons.
Very recently Kelley et al. demonstrated in mice that some
adverse effects like insulin resistance and non-alcoholic
fatty liver disease attributed to CLA may be due to the defi-
ciency of n-3 PUFA and that such adverse effects can be
corrected by a concomitant increase in the intake of α-
linolenic acid, an n-3 PUFA and flax seed oil, a rich natu-
ral source for this fatty acid [139]. Considering the
reported adverse events and safety concerns, Gaullier at al.
assessed the effects of supplementation of 3.4 g/d CLA
(1:1 ratio 9- and 10-CLA in triglyceride form) in 134
humans for 2 years [140]. The data revealed that CLA sup-
Table 2: Important biological effects of CLA in human subjects.
Treatment Effect Ref
CLA with creatine CLA and creatine as adjuncts increased mictochondrial function by reducing sarcopenia and 
decreased oxidative stress in older adults
[116]
CLA with ω-3 fatty acids prevents increased abdominal fat and increases fat-free mass and adiponectin. [28]
9-CLA No adverse effect on coronary vascular disease [126]
9-CLA Modest anti-inflammatroy effect in allegic subjects [32]
CLA with γ-oryzanol Reduced blood pressure and body fat. [127]
9-and 10-CLA Enhanced fat oxidation and energy expenditure during sleep [50]
10-CLA Anti-lipogenic effect in lactating women's mammary tissue [128]
CLA Reduce weight gain induced by psychotropic medication [129]
CLA Favourable effect on serum insulin, but no effect on body composition, energy expenditure of 
apetite.
[101]
CLA Increased resting metabolic rate, PPAR-γ and hormone-sensitive lipase [68]
CLA No effect on glucose metabolism or insulin sensitivity on obese population. [41]
Trans fatty acids (t-11/t-12, 18:1) Gender-based gene expression [59]
CLA Inhibition on leptin, adiponection - contribute to insulin resistance [26]
CLA and Calcium Reduces pregnancy-induced hypertension and decreases the intracellular concentration of ionised 
free calcium in peripheral blood lymphocytes.
[130]
CLA Do not beneficially change risk factors for cardiovascular disease or diabetes [94]
CLA and Vaccenic acid No effect on blood pressure or arterial elasticity in healthy young men. [131]
CLA Affect lipid and carbohydrate metabolism and reduced body weight [27]
CLA and other PUFA Possible role in preventing renal carcinoma [132]
CLA Reduce colorectal carcinoma [133]
CLA Enhanced immunological function [102,113]
CLA Enhanced C-reactive protein [43]
CLA Suppresses rheumatoid arthritis [109]
CLA Lipid peroxidation [124]
CLA Not good to treat metabolic syndrome [134]
CLA Not associated with breast cancer [76]
10-CLA Induces hyperproinsulinaemia, which predicts diabetes and cardiovascular disease [124]
CLA Ptotective effect on the risk of metastasis in breast cancer [75]
10-CLA Increases oxidative stress and inflammatroy biomarkers in obese men [135]
CLA Positive impact on cardioprotective effect. [89]
CLA Modulation of risk factor associated with atherosclerosis [125]Nutrition & Metabolism 2009, 6:36 http://www.nutritionandmetabolism.com/content/6/1/36
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plementation for 24 months in healthy, overweight adults
was well tolerated as revealed by the decreased body
weight and body fat mass, and increased circulating lipo-
protein, thrombocytes, and aspartate amino transferase.
There was no change in fasting blood glucose. Plasma
total cholesterol and LDL cholesterol were reduced,
whereas HDL cholesterol and triglycerides were
unchanged. The reported adverse effect rate was decreased
considerably in the 2-years long study, compared with the
initial 12 months of the study [140]. These results indicate
that most of the reported adverse effects are related to the
short-term studies in humans [140]. Apparently, many of
the physiological adverse effects like hyperinsulinemia
and fatty liver in mice were ameliorated with the inclusion
of increasing amounts of fish oil in the diets, which is a
rich source for very long-chain fatty acids [123]. These
results indicate that a mixture comprising all n-3, n-6
(CLA) and n-9 fatty acids in an appropriate proportion on
humans would be a better answer to avoid the reported
adverse effects of CLA.
Conclusion
The heterogeneity of both in vitro and in vivo evidences on
the efficacy of CLA studies makes it difficult to pin-point
whether CLA offer a 100% safe functional food. Obese
people are likely to consume more of these minor lipid
nutrients, irrespective of their high cost. Although com-
paratively few human clinical studies exist, it appears to
date that CLA are beneficial for human health. More
focused world-wide network clinical trials involving
probands and patients from all continents are required to
arrive at conclusive evidence. Another important aspect is
contrasting functionalities of CLA isomers and the fact
that a majority of clinical trials use a crude mixture of CLA
(predominated by 9- and 10-CLAs). Moreover, the
reported negative effects like fatty liver and spleen, induc-
tion colon carcinogenesis, are yet to be proved beyond
doubt. Furthermore, apart from PPAR-mediated signal-
ling, more conclusive evidences are necessary to unravel
other molecular mechanisms and complex signalling
pathways triggered by dietary CLA.
Strictly controlled studies as performed in animals or in
culture models may not be maintained in clinical trials,
however, most of human studies are based on blood,
blood cells, milk or biopsy specimens - all these would
cause probable variations in the general data generated.
Thus, conclusive studies focused on parameters such as
type of CLA isomer administered, variables measured,
mode of administration (eg., as free fatty acid or its triglyc-
eride form, liquid or solid), gender, age, and ethnical
background remain to be taken on prior to conclude that
CLA is a fool-proof functional food to humans. To this
end, a positive result is that recent studies emphasise a
combination of CLA with PUFA to be best formula to
ameliorate the adverse effects observed so far.
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